by winston » Mon Oct 04, 2021 9:26 pm
not vested
July 21, 2021
Shanghai Fosun Pharmaceutical Group (2196 HK / 600196 CH) - Progress in regulatory process for its mRNA Covid-19 vaccine
Established in 1994, Shanghai Fosun Pharma is an integrated healthcare group in China offering pharmaceutical products, medical devices and healthcare services via its hospital network, and the healthcare arm of Fosun Group.
Its vision is to become a first tier enterprise in the global mainstream pharmaceutical and healthcare market.
Fosun’s pharmaceutical portfolio contributed ~72% of 2020 revenues, while other key contributing segments were medical devices and healthcare services.
In terms of geography, ~73% of its FY20 revenues was derived from China.
While Fosun provides medium term exposure to China’s growing demand for healthcare driven by increasing disposable income and aging population trends, near term factors which may influence share price performance include market expectations for pricing pressure from ongoing healthcare sector reforms and higher expenses relating to its R&D and growth plans .
HOLD (2196 HK) / SELL (600196 CH).
Source: OCBC
It's all about "how much you made when you were right" & "how little you lost when you were wrong"